Market Overview

Credit Suisse Sees Continued Operational Progress For Kite Pharma

Related KITE
Kite Pharma Reports Patients with Relapsed, Refractory Acute Lymphoblastic Leukemia Showed Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor T Cells
Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints

In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating and $34.00 price target on Kite Pharma (NASDAQ: KITE).

In the report, Credit Suisse noted, “KITE continues to make progress toward an IND filing in 2014 and initiation of a pivotal study in H1:15. The ongoing NCI trial has been expanded to include DLBCL patients treated with cells that have undergone KITE's new freezing process. This is an important validation step for the freezing process because it is expected to be used in the pivotal study and in the commercial manufacuring procedure. KITE is continuing the technology transfer with its off-site manufacturing facility which will support manufacturing for the future multi-center pivotal study, and ultimately commercialization.”

Kite Pharma closed on Thursday at $22.22.

Latest Ratings for KITE

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Jul 2014Stifel NicolausInitiates Coverage onBuy
Jul 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Reiteration Analyst Ratings

 

Related Articles (KITE)

Around the Web, We're Loving...

Get Benzinga's Newsletters